Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1006 to 1020 of 1308 results for social care

  1. Abicipar pegol for treating wet age-related macular degeneration [ID1533]

    In development Reference number: GID-TA10511 Expected publication date: TBC

  2. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .

  3. Rimegepant for treating migraine (TA919)

    Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.

  4. Golimumab for the treatment of psoriatic arthritis (TA220)

    Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.

  5. Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

    Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.

  6. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia (TA1049)

    Evidence-based recommendations on blinatumomab (Blincyto) with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia in adults.

  7. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

  8. Pegcetacoplan for treating geographic atrophy [ID4041]

    Discontinued Reference number: GID-TA11351

  9. Public board meeting agenda and papers: December 2025

    Agenda and papers of the NICE public board meeting on 10 December 2025

  10. Public board meeting agenda and papers: July 2023

    Agenda and papers of the NICE public board meeting on 19 July 2023

  11. Public board meeting agenda and papers: March 2023

    Agenda and papers of the NICE public board meeting on 22 March 2023

  12. Public board meeting agenda and papers: March 2024

    Agenda and papers of the NICE public board meeting on 20 March 2024

  13. Public board meeting agenda and papers: December 2023

    Agenda and papers of the NICE public board meeting on 13 December 2023

  14. FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)

    NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .

  15. Is contingency management effective in reducing alcohol consumption in people who misuse alcohol compared with standard care?

    reducing alcohol consumption in people who misuse alcohol compared with standard care? Any explanatory notes(if applicable) Why this is...